If you're researching GLP-1 weight loss medications, you've probably come across two main options: semaglutide — sold as Ozempic and Wegovy — and tirzepatide, sold as Mounjaro and Zepbound. Both are highly effective. Both are injected weekly. Both have transformed the landscape of medically supervised weight loss. But they are not the same medication, and the differences matter when choosing what's right for your body.
At Meadow Primary Care, we prescribe both as part of our GLP-1 weight loss membership program in Bradenton and Lakewood Ranch. Here's what you need to know.
How Each Medication Works
Semaglutide
Semaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone that regulates appetite, slows gastric emptying, and improves blood sugar control. It targets one receptor pathway. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved specifically for chronic weight management at a higher dose.
Tirzepatide
Tirzepatide is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action appears to amplify both the weight loss and metabolic effects compared to GLP-1 agonism alone. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management.
How Do the Results Compare?
Clinical trial data shows tirzepatide produces greater average weight loss than semaglutide:
- Semaglutide (Wegovy): average weight loss of approximately 15–17% of body weight over 68 weeks in the STEP trials
- Tirzepatide (Zepbound): average weight loss of approximately 20–22% of body weight over 72 weeks in the SURMOUNT trials
That said, individual results vary significantly. Some patients respond better to semaglutide; others see dramatically better results with tirzepatide. Clinical data represents averages, not guarantees.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| FDA approval (weight) | Wegovy — approved | Zepbound — approved 2023 |
| Avg weight loss | ~15–17% | ~20–22% |
| Injection frequency | Once weekly | Once weekly |
| Starting dose titration | Gradual over 16–20 weeks | Gradual over 20 weeks |
| Common side effects | Nausea, GI symptoms | Nausea, GI symptoms (often milder) |
| Longer track record | Yes — more long-term data | Growing — newer to market |
Which One Should You Take?
This is exactly the conversation Meriem has with every patient during their initial evaluation. There's no one-size-fits-all answer, but here are factors that typically influence the decision:
- If you have type 2 diabetes: Both options have diabetes-approved versions; your blood sugar response may guide the choice
- If you've tried semaglutide before: Some patients who plateaued on semaglutide see renewed progress on tirzepatide
- If you're sensitive to GI side effects: Some patients tolerate tirzepatide better, though this varies
- If cost is a factor: Availability and pricing can differ — we'll discuss what's accessible within your membership
- If you want more clinical long-term data: Semaglutide has been on the market longer with more real-world evidence
Medication Is Included in Your Membership
At Meadow, your GLP-1 medication is included in your monthly weight loss membership — no separate pharmacy bills. We'll determine together whether semaglutide or tirzepatide is the right fit based on your labs, health history, and goals.
What About the Side Effects?
Both medications share similar side effect profiles — primarily gastrointestinal: nausea, mild bloating, reduced appetite, and sometimes loose stools, particularly early in treatment. These typically improve significantly as your body adjusts over the first 4–8 weeks and doses are titrated slowly.
Neither medication is appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Pancreatitis is a rare but serious risk that's discussed during your evaluation. This is why a proper medical evaluation — not a quick online questionnaire — matters before starting.
How to Get Started
If you're in Bradenton, Lakewood Ranch, Parrish, or Ellenton and want to explore GLP-1 weight loss therapy, the first step is a conversation. We start with labs, then an in-person evaluation, then determine together which medication fits your profile. Text us at (941) 340-1649 or visit meadowprimarycare.com to get started.
Two Locations Serving Manatee County
- Lakewood Ranch: 9030 58th Dr E, Suite 102, Bradenton, FL 34202
- Ellenton / Parrish: 7216 US-301 N, Suite 120, Ellenton, FL 34222
- Monday–Friday · 8:30 AM – 4:30 PM · Telehealth statewide across Florida
Frequently Asked Questions
On average, tirzepatide produces greater weight loss in clinical trials — approximately 20-22% vs 15-17% of body weight. However, individual results vary and some patients respond better to semaglutide. The right choice depends on your health history, goals, and how your body responds, which is why a medical evaluation is essential before starting either.
Yes, patients sometimes switch between GLP-1 medications if they plateau or experience side effects. This should always be done under medical supervision with appropriate monitoring. At Meadow Primary Care, Meriem manages all medication transitions as part of your membership.
Ozempic and Wegovy both contain semaglutide — Ozempic is FDA-approved for type 2 diabetes, Wegovy for weight management. Mounjaro and Zepbound both contain tirzepatide — Mounjaro for diabetes, Zepbound for weight management. The active ingredients are the same within each pair; the brand name and approved indication differ.
Yes. Semaglutide and tirzepatide are prescription medications that require a medical evaluation and provider prescription. At Meadow Primary Care in Manatee County, your prescription is included as part of your GLP-1 weight loss membership.
Most patients remain on GLP-1 medications long-term to maintain results, as weight often returns when the medication is discontinued. This is a conversation Meriem has with every patient based on their goals, health status, and individual response to treatment.
Ready for Healthcare That Actually Works?
Same-day appointments. 30+ minute visits. A provider who texts back. No insurance required.